Internal Medicine, Medical Oncology · Overland Park, KS
NPI
1497979678
Since 2007
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
10701 Nall Ave Ste 100
Overland Park, KS, 66211
Phone (913) 338-5585
Groups this clinician bills Medicare through
Medicare paid, 2024
$18K
278 services
Medicare patients, 2024
80
Average age 74
Drug cost, 2024
$4.2M
653 prescriptions
Company payments, 2025
$577
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ajjai S Alva was code 99214 (office e&m - established), 202 times for 70 patients. In total Ajjai S Alva billed 278 services in 9 codes, and Medicare paid $18K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-05-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 202 | 70 | $75.40 | $15K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 49 | 39 | $12.87 | $631 |
| 99204 Office E&M - New | Facility | 13 | 13 | $107.63 | $1,399 |
By year: 2022 $30K for 311 services; 2023 $19K for 248 services; 2024 $18K for 278 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ajjai S Alva prescribed most often to Medicare patients was Cabometyx (Cabozantinib S-Malate), with 103 prescriptions and refills. In total Ajjai S Alva wrote 653 Medicare prescriptions that cost $4.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Cabometyx Cabozantinib S-Malate | 103 | 103 | 16 | $2.4M |
| Abiraterone Acetate Generic | 61 | 65 | 11 | $56K |
| Prednisone Generic | 52 | 79 | 20 | $324 |
| Inlyta Axitinib | 37 | 37 | Under 11 | $511K |
| Prochlorperazine Maleate Generic | 35 | 36 | 19 | $1,213 |
| Xtandi Enzalutamide | 28 | 28 | Under 11 | $366K |
| Eliquis Apixaban | 26 | 32 | Under 11 | $17K |
| Amlodipine Besylate Generic | 24 | 52 | Under 11 | $241 |
| Levothyroxine Sodium Generic | 21 | 63 | 12 | $247 |
| Sunitinib Malate Generic | 21 | 21 | Under 11 | $105K |
| Hydrocortisone Generic | 19 | 47 | Under 11 | $1,005 |
| Lenvima Lenvatinib Mesylate | 18 | 18 | Under 11 | $420K |
| Ondansetron Odt Ondansetron | 16 | 16 | 13 | $543 |
| Everolimus Generic | 11 | 13 | Under 11 | $42K |
Brand drugs: 237 claims; generic drugs: 416 claims; opioid claims: 28.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ajjai S Alva $577 ($577 in general payments such as food, travel and fees) from 17 companies. The largest payer was Pfizer Inc. with $98.48.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 8 | $98.48 |
| Ferring Pharmaceuticals Inc. | 2 | $72.49 |
| Merck Sharp & Dohme LLC MRK | 2 | $66.08 |
| Janssen Biotech, Inc. JNJ | 2 | $45.82 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 2 | $41.54 |
| Verity Pharmaceuticals Inc. | 2 | $34.48 |
| Eisai Inc. 4523.T | 2 | $31.45 |
| Urogen Pharma, Inc. URGN | 1 | $24.42 |
| Sumitomo Pharma America, Inc. 4506.T | 1 | $23.01 |
| Endo USA, Inc. | 1 | $22.62 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.